REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
361.87
-4.36 (-1.19%)
As of 4:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close366.23
Open365.00
Bid363.45 x 800
Ask368.00 x 1200
Day's Range361.19 - 369.00
52 Week Range281.89 - 505.49
Volume499,644
Avg. Volume805,615
Market Cap39.062B
Beta1.58
PE Ratio (TTM)26.27
EPS (TTM)13.77
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est406.05
Trade prices are not sourced from all markets
  • Business Wire2 hours ago

    Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc. (REGN) today announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip. “We are encouraged by these data and look forward to advancing our pivotal Phase 3 fasinumab program in patients with osteoarthritis of the knee or hip, who currently have very limited therapeutic choices to treat their chronic pain, other than with non-steriodal anti-inflammatory drugs or opioids,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron.

  • PR Newswire2 hours ago

    Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip. Fasinumab-treated patients experienced significantly less pain and significantly improved functional ability from baseline compared to placebo. "We are encouraged by these data and look forward to advancing our pivotal Phase 3 fasinumab program in patients with osteoarthritis of the knee or hip, who currently have very limited therapeutic choices to treat their chronic pain, other than with non-steriodal anti-inflammatory drugs or opioids," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron.

  • Know This Sell Signal: When Stock Leaders Stage Big Downside Reversals
    Investor's Business Daily3 days ago

    Know This Sell Signal: When Stock Leaders Stage Big Downside Reversals

    SunPower in 2007, Regeneron Pharmaceuticals in 2015, and Randgold in 2016 both triggered an important sell signal: a sharp reversal to the downside in unusually heavy volume.

  • Zacks2 days ago

    Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD

    Regeneron (REGN) suffers setback as the FDA issues a CRL to its application for label expansion of Eylea for wet AMD with a modified 12-week dosing schedule.

  • Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential
    Zacks2 days ago

    Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential

    Regeneron Pharmaceuticals (REGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

  • OPKO Health Expects Its Loss per Share to Shrink This Year
    Market Realist3 days ago

    OPKO Health Expects Its Loss per Share to Shrink This Year

    In the third quarter, OPKO Health (OPK) expects research and development expenses of $33 million–$38 million, and foresees its total operating expenses falling to $285 million–$305 million. The company has projected a single-digit effective tax rate for Q3 2018. In fiscal 2018, analysts expect OPKO Health’s adjusted diluted EPS to rise ~51.0% to -$0.24, while peers Novartis (NVS), Merck (MRK), and Regeneron (REGN) are expected to report adjusted diluted EPS of approximately $5.20, $2.60, and $20.40, respectively.

  • OPKO Health’s Q3 2018 Revenue Expectations
    Market Realist3 days ago

    OPKO Health’s Q3 2018 Revenue Expectations

    In the third quarter, OPKO Health (OPK) expects service revenue of $200 million–$220 million, assuming stable reimbursement rates and a small rise in volumes. Meanwhile, the company expects product revenue of $28 million–$32 million, and Rayaldee revenue of $5.7 million–$6.5 million.

  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of REGN earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Regeneron Pharmaceuticals Inc Earnings Call

  • What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
    Market Realist3 days ago

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    Alnylam Pharmaceuticals’ (ALNY) investigational RNAi therapeutic drug lumasiran is being developed for the treatment of primary hyperoxaluria type 1 (or PH1). Alnylam expects to initiate a Phase 3 trial of the drug in 2018, with its results expected in late 2019.

  • PR Newswire3 days ago

    Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration

    TARRYTOWN, N.Y., Aug. 13, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that due to ongoing labeling discussions the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD). The sBLA was based on the second year data from the VIEW studies during which patients were treated with a modified 12 week dosing schedule (doses given at least every 12 weeks and additional doses as needed). Regeneron expects to complete these discussions and receive a final FDA action within approximately two months.

  • What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates
    Market Realist6 days ago

    What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates

    Alnylam Pharmaceuticals’ (ALNY) interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

  • Motley Fool6 days ago

    Carl Icahn Fires Shots at Express Scripts

    Billionaire activist-investor Carl Icahn thinks Cigna’s planned tie-up with Express Scripts is a big blunder.

  • Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
    Market Realist7 days ago

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.

  • 7 "Zombie Stocks" That Are Coming Back to Life
    Kiplinger7 days ago

    7 "Zombie Stocks" That Are Coming Back to Life

    Just because a stock has performed badly in the past, doesn't mean it's game over for the future. As investors, we can jump into stocks that are rising. But another strategy is to find poorly performing stocks on the cusp of rebounding. Obviously, this is a more risky approach. What happens if the poor results continue? Well, for instance, you can generate seriously lucrative returns. The key is to cherry-pick your stocks wisely by differentiating between stocks unfairly treated by the market, versus the stocks where all hope is truly lost. Luckily help is at hand. Here, I turned to top analyst ratings to pinpoint stocks that are worth a second look. I used TipRanks to focus on analysts with the sharpest stock picking abilities. These stocks have all posted losses, but the upside potential remains intact. Let's take a closer look at these rebounding stock picks now: SEE ALSO FROM KIPLINGER: 10 of the Market's Most Shorted Stocks

  • What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
    Market Realist8 days ago

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.

  • A Look at Ionis’s Revenue Streams in the Second Quarter
    Market Realist8 days ago

    A Look at Ionis’s Revenue Streams in the Second Quarter

    As discussed earlier, Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to revenues of $112 million during the second quarter of 2017. Ionis missed Wall Street analyst estimates for revenues and EPS in Q2 2018. Ionis reported commercial revenues of $57 million during Q2 2018, over 100% growth as compared to commercial revenues of $24 million during the second quarter of 2017.

  • See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGN

  • Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
    Zacks8 days ago

    Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

    The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.

  • Why this company's Durham outpost may benefit from $100M investment
    American City Business Journals9 days ago

    Why this company's Durham outpost may benefit from $100M investment

    Massachusetts-based gene therapy company bluebird bio – which is growing in Durham – has inked a $100 million deal for the development of treatments for cancer.

  • What to Expect from Sarepta’s Second-Quarter Earnings
    Market Realist9 days ago

    What to Expect from Sarepta’s Second-Quarter Earnings

    Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company. Sarepta develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases.

  • Investor's Business Daily10 days ago

    Can These Biotech Companies Catch Novartis, Gilead In CAR-T?

    Regeneron Pharmaceuticals is investing $100 million in Bluebird Bio in an immuno-oncology collaboration that could rival the likes of Novartis and Gilead Sciences.

  • Analysts Are Mostly Positive on Neurocrine Biosciences in August
    Market Realist10 days ago

    Analysts Are Mostly Positive on Neurocrine Biosciences in August

    In July 2018, the FDA approved AbbVie’s (ABBV) and Neurocrine Biosciences’ (NBIX) Orilissa for the treatment of women with moderate to severe endometriosis. Orlissa (elagolix) is the first and only GnRH (gonadotropin-releasing hormone) antagonist approved for the treatment of moderate-to-severe endometriosis pain in women.

  • T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch
    Zacks10 days ago

    T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch

    Ryan McQueeney highlights today's trending stories, including the departure of PepsiCo's CEO, Jamie Dimon's latest public wisdom, and Bluebird Bio's new partnership. Later, he recaps recent developments in the T-Mobile-Sprint merger and previews what the combined company might look like.

  • How Neurocrine Biosciences Performed in the Second Quarter
    Market Realist10 days ago

    How Neurocrine Biosciences Performed in the Second Quarter

    Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.

  • Barrons.com10 days ago

    Small Biotechs See Big Gains as Bluebird, Intercept Fly

    Smaller biotechs are rising, following the announcement of a collaboration between bluebird bio (BLUE) and Regeneron Pharmaceuticals to tackle cancer and a double upgrade for Intercept Pharmaceuticals (ICPT). Bluebird bio (BLUE) is soaring on news that Regeneron Pharmaceuticals said it would make a $100 million investment in the biotech's stock at $238.10 a share, which represents a 59% premium over bluebird's Friday closing price.  The two companies plan to collaborate on new immune cell therapies for cancer treatment over a period of five years.  Bluebird is up 4.2% to $156.26 in recent trading, while Regeneron is falling 0.6% to $392.42. In addition, Intercept Pharmaceuticals (ICPT) was on the receiving end of a double upgrade from Goldman Sachs.